Prostate Cancer - Results from #100

Stereotactic body radiotherapy for lung oligometastatic prostate cancer: An international retrospective multicenter study. April 4, 2025

Analytical and Real-World Clinical Characterization of S2,3PSA% Test in MRI Fusion Targeted Prostate Biopsy Population. April 4, 2025

Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluation. April 4, 2025

High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes. April 3, 2025

Toward a Refined PI-RADS: The Feasibility and Limitations of More Informative Metrics in Reviewing MRI Scans. April 3, 2025

Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study. April 3, 2025

Targeting the tumour cell surface in advanced prostate cancer. April 3, 2025

Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study. April 3, 2025

Advances in PSMA-Targeted Radionuclide Therapeutics. April 3, 2025

Lower Testosterone level and metastases-free survival in nmCRPC patients treated with novel antiandrogens: A post-hoc analysis of SPARTAN and ARAMIS. April 3, 2025

PSMA-PET guided Intra-prostatic Boost in Prostate SBRT (PROBE): A phase II trial. April 3, 2025

Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients. April 2, 2025

Treatment Noncompletion and Shorter Radiation Regimens Among US Patients With Prostate Cancer: A Focus on Asian American and Pacific Islander Patients. April 2, 2025

Racial variation in the advanced prostate cancer genome. April 2, 2025

Prospective comparison of 18F-PSMA-1007 PET/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer. April 2, 2025

Causes of evolutionary divergence in prostate cancer. April 2, 2025

Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial. April 1, 2025

Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study. April 1, 2025

Emulating an Existing Trial of Treatments for Prostate Cancer Using Real-World Data: Challenges and lessons learned. April 1, 2025

Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial. April 1, 2025

Page 6 of 1474